Table 3 Anti-c-Met therapies currently under investigation in clinical trials for breast cancer [11]
From: The clinical and functional significance of c-Met in breast cancer: a review
Compound | Target/mechanism of action | ClinicalTrials.gov identifier |
|---|---|---|
Tivantinib (ARQ197) | c-Met/non-ATP kinase inhibitor | NCT 01575522 |
Cabozantinib (XL184) | c-Met and VEGFR, along with RET, KIT, AXL/kinase inhibitor | NCT 01738438 |
Foretinib (XL880) | c-Met and VEGFR, along with KIT, Flt-3, PDGFR, Tie-2/kinase inhibitor | NCT 01147484 |
MetMab (onartuzumab) | c-Met/anti-c-Met antibody | NCT 01186991 |